Beam Therapeutics BEAM Interest And Other Income Expense Net
Interest And Other Income Expense Net at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept beam:InterestAndOtherIncomeExpenseNet.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's interest and other income expense net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's interest and other income expense net?
- Beam Therapeutics (BEAM) reported interest and other income expense net of $9.87M in Q1 2026.
- How has Beam Therapeutics's interest and other income expense net changed year-over-year?
- Beam Therapeutics's interest and other income expense net increased by 0.0% year-over-year, from $9.86M to $9.87M.
- What is the long-term trend for Beam Therapeutics's interest and other income expense net?
- Over 3 years (2022 to 2025), Beam Therapeutics's interest and other income expense net has grown at a 41.9% compound annual growth rate (CAGR), from $15.3M to $43.73M.
- What does interest and other income expense net mean?
- This metric aggregates interest income earned on cash and investment balances, interest expenses on debt obligations, and other miscellaneous non-operating income or expenses. It serves as a measure of the company's non-core financial activities and the net cost or benefit of its capital structure. Monitoring this helps investors understand the impact of treasury management and debt servicing on overall profitability.